Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Ironwood Pharmaceuticals Inc IRWD

Healthcare Biotechnology

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of... see more

Add To Watchlist

Recent & Breaking News (NDAQ:IRWD)

Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

Business Wire June 6, 2018

Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week® 2018

Business Wire June 5, 2018

Ironwood Pharmaceuticals Announces Results of 2018 Annual Meeting of Shareholders

Business Wire May 31, 2018

Sarissa Capital Issues Statement On Ironwood Pharmaceuticals

PR Newswire May 31, 2018

Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week® 2018

Business Wire May 23, 2018

Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees

Business Wire May 14, 2018

Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value

Business Wire May 9, 2018

Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals — What Drives Growth in Today's Competitive Landscape

GlobeNewswire May 7, 2018

Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Business Wire May 3, 2018

Ironwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to Shareholders

Business Wire May 2, 2018

Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action

PR Newswire May 1, 2018

Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase (sGC) Business from Commercial and Gastrointestinal Business

Business Wire May 1, 2018

Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update

Business Wire May 1, 2018

Ironwood Pharmaceuticals to Host First Quarter 2018 Investor Update Call

Business Wire April 17, 2018

Ironwood Pharmaceuticals Announces Director Nomination from Sarissa Capital

Business Wire April 9, 2018

Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences

Business Wire March 5, 2018

Analysis: Positioning to Benefit within Ironwood Pharmaceuticals, Altaba, The AES, PACCAR, NVR, and WPX Energy — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire March 5, 2018

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update

Business Wire February 15, 2018

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update Call

Business Wire February 1, 2018

Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Business Wire January 16, 2018